Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Recombinant antihemophilic factor plasma/albumin-free method: Phase II/III data; under review in EU, U.S., Canada and Switzerland

In an ongoing, open-label Phase II/III trial in 41 patients

Read the full 108 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE